{"id":491477,"date":"2024-05-22T09:29:44","date_gmt":"2024-05-22T09:29:44","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/491477\/advanced-cervical-cancer-pipeline-assessment-2024-update-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-approvals-treatment-outlook-key-companies.html"},"modified":"2024-05-22T09:29:44","modified_gmt":"2024-05-22T09:29:44","slug":"advanced-cervical-cancer-pipeline-assessment-2024-update-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-approvals-treatment-outlook-key-companies","status":"publish","type":"post","link":"https:\/\/www.oklahomanews-online.com\/news\/story\/491477\/advanced-cervical-cancer-pipeline-assessment-2024-update-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-approvals-treatment-outlook-key-companies.html","title":{"rendered":"Advanced Cervical Cancer Pipeline Assessment, 2024 Update | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest Approvals, Treatment Outlook, Key Companies"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\">\n<div><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/uploads\/1716301132.jpeg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Advanced Cervical Cancer Pipeline Assessment, 2024 Update | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest Approvals, Treatment Outlook, Key Companies\" src=\"https:\/\/www.abnewswire.com\/uploads\/1716301132.jpeg\" alt=\"Advanced Cervical Cancer Pipeline Assessment, 2024 Update | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest Approvals, Treatment Outlook, Key Companies\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px;border:0 solid !important\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Advanced Cervical Cancer Pipeline Insights<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic;padding:8px 0px\">As per DelveInsight\u2019s assessment, globally, about 70+ key pharma and biotech companies are working on 75+ pipeline drugs in the Advanced Cervical Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify\">&ldquo;<a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/report-store\/advanced-cervical-cancer-pipeline-insight?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Advanced Cervical Cancer Pipeline Insight, 2024<\/strong><\/a>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Advanced Cervical Cancer Market.<\/p>\n<p style=\"text-align: justify\">The Advanced Cervical Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify\"><strong>Advanced Cervical Cancer Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>The report provides insights into:<\/strong><\/p>\n<p style=\"text-align: justify\">The report provides detailed insights into the emerging therapies for the treatment of Advanced Cervical Cancer and the aggregate therapies developed by major pharma companies.<\/p>\n<p style=\"text-align: justify\">It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<p style=\"text-align: justify\">It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<p style=\"text-align: justify\">The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/p>\n<p style=\"text-align: justify\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Advanced Cervical Cancer market.<\/p>\n<p style=\"text-align: justify\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify\">Advanced Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as &ndash;<\/p>\n<p style=\"text-align: justify\">Oral<\/p>\n<p style=\"text-align: justify\">Parenteral<\/p>\n<p style=\"text-align: justify\">Intravenous<\/p>\n<p style=\"text-align: justify\">Subcutaneous<\/p>\n<p style=\"text-align: justify\">Topical<\/p>\n<p style=\"text-align: justify\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify\">Products have been categorized under various Molecule types, such as &ndash;<\/p>\n<p style=\"text-align: justify\">Monoclonal Antibody<\/p>\n<p style=\"text-align: justify\">Peptides<\/p>\n<p style=\"text-align: justify\">Polymer<\/p>\n<p style=\"text-align: justify\">Small molecule<\/p>\n<p style=\"text-align: justify\">Gene therapy<\/p>\n<p style=\"text-align: justify\"><strong>Advanced Cervical Cancer Emerging Therapies Mechanism of Action (MOA) Types:<\/strong><\/p>\n<p style=\"text-align: justify\">Programmed cell death-1 receptor antagonists<\/p>\n<p style=\"text-align: justify\">DNA synthesis inhibitors<\/p>\n<p style=\"text-align: justify\">Transforming growth factor-beta inhibitors<\/p>\n<p style=\"text-align: justify\">T lymphocyte replacements<\/p>\n<p style=\"text-align: justify\">CD4-positive T lymphocyte stimulant<\/p>\n<p style=\"text-align: justify\">Programmed cell death-1 ligand-1 inhibitor<\/p>\n<p style=\"text-align: justify\">Antigen-presenting cell modulators<\/p>\n<p style=\"text-align: justify\">Immunostimulants<\/p>\n<p style=\"text-align: justify\"><strong>Analysis of Emerging Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify\">The report covers the emerging products under different phases of clinical development &ndash;<\/p>\n<p style=\"text-align: justify\">Late-stage products (Phase III)<\/p>\n<p style=\"text-align: justify\">Mid-stage products (Phase II)<\/p>\n<p style=\"text-align: justify\">Early-stage product (Phase I)<\/p>\n<p style=\"text-align: justify\">Pre-clinical and Discovery stage candidates<\/p>\n<p style=\"text-align: justify\">Discontinued &amp; Inactive candidates<\/p>\n<p style=\"text-align: justify\"><strong>Learn How the Ongoing Clinical &amp; Commercial Activities will Affect the Advanced Cervical Cancer Therapeutic Segment @ <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-cervical-cancer-pipeline-insight?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=kpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/advanced-cervical-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Advanced Cervical Cancer Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify\">There are approx. 70+ key companies developing therapies for Advanced Cervical Cancer. AstraZeneca is leading the therapeutics market with its Advanced Cervical Cancer drug candidates in the most advanced stage of clinical development.<\/p>\n<p style=\"text-align: justify\"><strong>The Leading Companies in the Advanced Cervical Cancer Therapeutics Market Include:<\/strong><\/p>\n<p style=\"text-align: justify\">AstraZeneca<\/p>\n<p style=\"text-align: justify\">GlaxoSmithKline<\/p>\n<p style=\"text-align: justify\">Advaxis<\/p>\n<p style=\"text-align: justify\">Bristol-Myers Squibb<\/p>\n<p style=\"text-align: justify\">Innovent Biologics<\/p>\n<p style=\"text-align: justify\">Shanghai Henlius Biotech<\/p>\n<p style=\"text-align: justify\">Biocad<\/p>\n<p style=\"text-align: justify\">Genexine, Inc.<\/p>\n<p style=\"text-align: justify\">Merck KGaA<\/p>\n<p style=\"text-align: justify\">Zeria Pharmaceutical<\/p>\n<p style=\"text-align: justify\">ISA Pharmaceuticals<\/p>\n<p style=\"text-align: justify\">Agenus Inc.<\/p>\n<p style=\"text-align: justify\">Chia Tai Tianqing Pharmaceutical Group Co., Ltd.<\/p>\n<p style=\"text-align: justify\">Vaccibody AS<\/p>\n<p style=\"text-align: justify\">Fujifilm Pharmaceuticals U.S.A., Inc.<\/p>\n<p style=\"text-align: justify\">NETRIS Pharma<\/p>\n<p style=\"text-align: justify\">CSPC ZhongQi Pharmaceutical Technology Co., Ltd.<\/p>\n<p style=\"text-align: justify\">Xencor, Inc.<\/p>\n<p style=\"text-align: justify\">Sotio a.s.<\/p>\n<p style=\"text-align: justify\">Andes Biotechnologies<\/p>\n<p style=\"text-align: justify\">And Many Others<\/p>\n<p style=\"text-align: justify\"><strong>Advanced Cervical Cancer Therapies Covered in the Report Include:<\/strong><\/p>\n<p style=\"text-align: justify\">Imfinzi (durvalumab): AstraZeneca<\/p>\n<p style=\"text-align: justify\">Dostarlimab: GlaxoSmithKline<\/p>\n<p style=\"text-align: justify\">Andes 1537: Andes Biotechnologies<\/p>\n<p style=\"text-align: justify\">PDS 0101: PDS Biotechnology Corporation<\/p>\n<p style=\"text-align: justify\">Cemiplimab: Regeneron Pharmaceuticals<\/p>\n<p style=\"text-align: justify\">DeTIL 0255: Nurix<\/p>\n<p style=\"text-align: justify\">Z-100: Zeria Pharmaceutical<\/p>\n<p style=\"text-align: justify\">And Many More<\/p>\n<p style=\"text-align: justify\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-cervical-cancer-pipeline-insight?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=kpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/advanced-cervical-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify\">1. Report Introduction<\/p>\n<p style=\"text-align: justify\">2. Executive Summary<\/p>\n<p style=\"text-align: justify\">3. Advanced Cervical Cancer Current Treatment Patterns<\/p>\n<p style=\"text-align: justify\">4. Advanced Cervical Cancer &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify\">6. Advanced Cervical Cancer Late-Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify\">7. Advanced Cervical Cancer Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify\">8. Advanced Cervical Cancer Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify\">10. Inactive Products<\/p>\n<p style=\"text-align: justify\">11. Dormant Products<\/p>\n<p style=\"text-align: justify\">12. Advanced Cervical Cancer Discontinued Products<\/p>\n<p style=\"text-align: justify\">13. Advanced Cervical Cancer Product Profiles<\/p>\n<p style=\"text-align: justify\">14. Key Companies in the Advanced Cervical Cancer Market<\/p>\n<p style=\"text-align: justify\">15. Key Products in the Advanced Cervical Cancer Therapeutics Segment<\/p>\n<p style=\"text-align: justify\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify\">17. Advanced Cervical Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify\">18. Advanced Cervical Cancer Future Perspectives<\/p>\n<p style=\"text-align: justify\">19. Advanced Cervical Cancer Analyst Review<\/p>\n<p style=\"text-align: justify\">20. Appendix<\/p>\n<p style=\"text-align: justify\">21. Report Methodology<\/p>\n<p style=\"text-align: justify\"><strong>Download Sample PDF to Explore the Key Offerings of the Report: <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/report-store\/advanced-cervical-cancer-pipeline-insight?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=kpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/advanced-cervical-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p class=\"caps\"><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=advanced-cervical-cancer-pipeline-assessment-2024-update-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-approvals-treatment-outlook-key-companies\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=advanced-cervical-cancer-pipeline-assessment-2024-update-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-approvals-treatment-outlook-key-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Advanced Cervical Cancer Pipeline Insights As per DelveInsight\u2019s assessment, globally, about 70+ key pharma and biotech companies are working on 75+ pipeline drugs in the Advanced Cervical Cancer therapeutics landscape<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts\/491477"}],"collection":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/comments?post=491477"}],"version-history":[{"count":0,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts\/491477\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/media?parent=491477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/categories?post=491477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/tags?post=491477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}